モルモット胆嚢の各種ホスホジエステラーゼ阻害剤による収縮抑制と環状ヌクレオチド含量の変化

  • KANEDA Takeharu
    Division of Veterinary Pharmacology, Nippon Veterinary and Animal Science University
  • WATANABE Akitoshi
    Division of Veterinary Pharmacology, Nippon Veterinary and Animal Science University
  • SHIMIZU Kazumasa
    Division of Veterinary Pharmacology, Nippon Veterinary and Animal Science University
  • URAKAWA Norimoto
    Division of Veterinary Pharmacology, Nippon Veterinary and Animal Science University
  • NAKAJYO Shinjiro
    Division of Veterinary Pharmacology, Nippon Veterinary and Animal Science University

書誌事項

タイトル別名
  • Effects of Various Selective Phosphodiesterase Inhibitors on Carbachol-Induced Contraction and Cyclic Nucleotide Contents in the Guinea Pig Gall Bladder

この論文をさがす

抄録

The effects of various selective phosphodiesterase (PDE) inhibitors on muscle contractility and cyclic nucleotide contents in the guinea pig gall bladder were investigated. Various selective PDE inhibitors, vinpocetine (type 1), erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA, type 2), milrinone (type 3), Ro20-1724 (type 4), and zaprinast (type 5), inhibited CCh-induced contractions in a concentration-dependent manner. The rank order of potency for the gall bladder was Ro20-1724 > vinpocetine > EHNA > milrinone > zaprinast, which was different from that of the trachea, taenia coli, and aorta. In the presence of CCh (0.3 μM), vinpocetine, milrinone, and Ro20-1724 each increased cAMP content, but not cGMP. By contrast, zaprinast increased cGMP content, but not cAMP, and EHNA increased both cAMP and cGMP contents. These results suggest that vinpocetine-, milrinone-, and Ro20-1724-induced relaxation was correlated with cAMP, zaprinast-induced relaxation was correlated with cGMP, and that EHNA-induced relaxation was correlated with cAMP and cGMP in the guinea pig gall bladder. In conclusion, the effect of PDE inhibitors in the guinea pig gall bladder was different from those in smooth muscles, such as the trachea, taenia coli, and aorta.<br>

収録刊行物

被引用文献 (2)*注記

もっと見る

参考文献 (39)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ